The most frequent ones among these patients were criteria E3 (vitamin D and calcium supplement in patients with known osteoporosis, previous fragility fracture(s), and/or bone mineral density (T-scores more than −2.5 in multiple sites)) with 34.3%; criteria A6 (angiotensin-converting enzyme (ACE) inhibitor with systolic heart failure and/or documented coronary artery disease) with 9.7%; and A8 (appropriate beta-blocker (bisoprolol, nebivolol, metoprolol, or carvedilol) with stable systolic heart failure) with 7%. Here, ACE is linked to systolic heart failure.